Effect of curcumin supplement in patients with beta thalassemia major
Phase 2
- Conditions
- Beta thalassemia major.Beta thalassaemia
- Registration Number
- IRCT2016053028165N1
- Lead Sponsor
- ational Nutrition and Food Technology Research Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 64
Inclusion Criteria
age between 18 and 40, Regular blood transfusions based on prescription, consumption of deferoxamine as an iron chelator drug, Not taking any nutritional supplements from 3 months before the start of the study, patients without hepatitis B, C, HIV and chronic kidney and heart diseases, not using other chelator medication except deferoxamine.
Excluson criteria: A significant change in dose of deferoxamine therapy during the study, using another iron chelator drug in addition to deferoxamine and pregnancy
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method